PremiumThe FlyCytokinetics regulatory update ‘incrementally positive,’ says Morgan Stanley RBC Capital stays bullish on Cytokinetics on lack of AdCom in aficamten view Cytokinetics says FDA does not plan advisory committee meeting for aficamten NDA PremiumCompany AnnouncementsCytokinetics’ Earnings Call: Progress Amid Challenges Cytokinetics: Strategic Positioning and Promising Developments Justify Buy Rating Cytokinetics Gains ‘Buy’ Rating Amid Strategic Advancements and Promising Clinical Developments PremiumThe FlyCytokinetics reports Q4 EPS ($1.26), consensus ($1.17) Cytokinetics (CYTK) Q4 Earnings Cheat Sheet Buy Recommendation for Cytokinetics Based on Competitive Advantage in Cardiovascular Treatments 
